The ASIST study will assess the safety and efficacy of BXQ-350 plus SOC, modified FOLFOX7 (mFOLFOX7) and bevacizumab, in patients with newly diagnosed mCRC. The study is also evaluating whether the ...

JonesTrading analyst Debanjana Chatterjee has reiterated their bullish stance on NTLA stock, giving a Buy rating on November 13. Debanjana ...

And these data are really quite interesting and impressive that if you don't progress and that your time on [enfortumab ...

Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a novel class of biologic therapy to ...

University of Sheffield spinout company, Rinri Therapeutics, a company focused on developing new treatments for hearing loss ...

Generic medications reduce the out-of-pocket (OOP) costs for common neurological conditions, apart from multiple sclerosis.

A study conducted at the Federal University of São Paulo (UNIFESP) in Brazil has concluded that the use of monochromatic ...

The study was conducted at the Federal University of São Paulo and involved 144 diabetic patients, who were treated with ...

Chemotherapy-induced peripheral neuropathy (CIPN) is a common adverse effect for patients undergoing cancer treatments, and ...

If you’re suffering from stabbing pain, numbness, tingling or a burning sensation in your arms, legs, hands or feet, you may ...

In May 2024, Zai Lab announced that the Centre for Drug Evaluation (CDE) accepted the sBLA with priority review designation for VYVGART Hytrulo for CIDP in China. The CDE granted the Breakthrough ...